news
TAmiRNA and advanceCOR receive Eurostars project “thrombomiR”
TAmiRNA and advanceCOR, a drug developing biotechnology company which focuses on personalized medicine in cardiovascular diseases, receive Eurostars project entitled: ”A novel microRNA-based platelet function biomarker for personalized anti-thrombotic treatment”. The aim of the Eurostars project is to validate the use of the thrombomiR™ kit for management of anti-thrombotic therapies. The thrombomiR™ kit is a minimally invasive blood test that can determine changes [...]
TAmiRNA is part of the international IMI2 project “Translational Safety Biomarker Pipeline”
Early and reliable detection and monitoring of adverse events is essential for improving of patient safety, reducing late attrition of drug candidates, and enhancing understanding of toxic mechanisms. The Translational Safety Biomarker Pipeline (TransBioLine) project will focus on development of biomarkers of injury for liver, kidney, pancreas, vasculature, central nervous system (CNS) and the development of non-invasive microRNA biomarkers using liquid biopsies. The [...]
Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures.
We want to draw your attention to the latest publication of the Department of Surgery, Medical University of Vienna, in cooperation with TAmiRNA GmbH, in Hepatology. "Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures." Hepatology. 2019 Jun;69(6):2636-2651. Personalized medicine in liver surgery. Together with colleagues from Medical University Vienna we could show that plasma levels of three miRNAs can accurately predict liver dysfunction [...]
Ask the Expert: kit or service, NGS or qPCR – what is the best choice for my microRNA biomarker project?
Can't find the answer to your question on our site? Not sure which method is right for your research? Get in touch with our experts at TAmiRNA - they will answer your questions and help to move from your ideas to results. Get in touch
Eager to learn more about TAmiRNA qPCR kits and the exciting field of microRNAs?
Click here to read our Technotes
TAmiRNA receives FFG EARLY STAGE for the development of novel theranostic solutions based on microRNA biomarkers – the PATH project.
PATH stands for "Project for Advancing the Application of MicroRNAs as THeranostic Biomarkers". The aim of this project is to create optimal framework conditions for successful research and development of the application of microRNAs as theranostic biomarkers. “Theranostics” means the increasingly close integration of diagnostics and therapy. The aim of theranostics is to enable the right therapy for the right patient at the [...]
Improving Quality Of Life For Patients With Osteoporosis Using MicroRNAs
We want to draw your attention to our latest article “Improving Quality Of Life For Patients With Osteoporosis Using MicroRNAs” Our simulations provide evidence for the utility of the osteomiR™ test for fracture risk assessment, and, furthermore, highlight the general potential of circulating microRNAs to be exploited as minimal-invasive diagnostic tools. Click here to read the study
New evidence for associations between miRNAs and metabolic unhealthy conditions
We want to draw your attention to the latest publication in cooperation with TAmiRNA GmbH, in Obesity Surgery.” Reduction of Premature Aging Markers After Gastric Bypass Surgery in Morbidly Obese Patients.” The findings indicate a significant reduction of the proinflammatory SASP after bariatric surgery. An increase in telomere length and reduced oxidative stress at telomeres was observed. Moreover, miR10a-5p which is downregulated during [...]
Serum levels of bone-related microRNAs and their association to bone microstructure and histomorphometry
We want to draw your attention to the latest publication of the VINFORCE research Group in cooperation with TAmiRNA GmbH, in Scientific Reports from Nature. “Bone-related circulating microRNAs miR-29b-3p, miR-550a-3p, and miR-324-3p and their association to bone microstructure and histomorphometry.” Scientific Reports, Volume 8,4867 (2018) MicroRNAs are promising new biomarkers for bone diseases. The findings enhance the potential value of circulating miRNAs as [...]
TAmiRNA & Vivomicx announce the introduction of new technology to make preclinical drug discovery and drug development more efficient.
TAmiRNA & Vivomicx have combined their technologies of laser microdissection and high sensitivity qPCR, which enables the quantitative analysis of cell-type specific RNA expression in complex tissues. Using this protocol TAmiRNA & Vivomicx have already been able to demonstrate: the profound difference of RNA expression between whole tumor and subsets of cells within the tumor and the large heterogeneity in RNA expression between colorectal* [...]